Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468466 | 0.72 | ATM (0.32) | MAPTATMMEN1KMT2APOLB | |
| SCHEMBL20465367 | 0.71 | SLC22A1 (0.32) | ALDH1A1ATMMEN1KMT2APOLB | |
| SCHEMBL7061157 | 0.70 | ALDH1A1 (0.39) | MAPTALDH1A1GLAATMMEN1 | |
| SCHEMBL13292181 | 0.69 | BRD4 (0.33) | MAPTALDH1A1GLAATMBRD4 | |
| SCHEMBL38663307 | 0.69 | SMN1; SMN2 (0.32) | ATMSLC22A1OPRM1SMN1; SMN2 | |
| SCHEMBL7175636 | 0.67 | ALDH1A1 (0.36) | MAPTALDH1A1GLAATMMEN1 | |
| SCHEMBL200228 | 0.67 | CYP2C19 (0.40) | BRD4POLBLMNAMAPK1SLC22A1 | |
| SCHEMBL16110306 | 0.66 | OPRM1 (0.40) | MAPTALDH1A1LMNAOPRM1SMN1; SMN2 | |
| SCHEMBL57714 | 0.66 | TSHR (0.49) | MAPTALDH1A1GLAMEN1KMT2A | |
| SCHEMBL8945270 | 0.65 | L3MBTL1 (0.34) | MAPTALDH1A1GLAATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127520-A1 | METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION | ZEON CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-9850325-B2 | Method for producing ring-opening metathesis polymer hydride, and resin composition | ZEON CORPORATION (JP) | 2017-12-26 | — | — | US | disclosed |
| EP-2270063-B1 | PROCESS FOR PRODUCING HYDROGENATED PRODUCT OF CYCLIC OLEFIN POLYMER PREPARED THROUGH RING-OPENING POLYMERIZATION | ZEON CORP (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-20150051353-A1 | METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION | ZEON CORPORATION (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2826802-A1 | METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION | Zeon Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1197509-B1 | PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | ZEON CORP (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-2270063-A2 | Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization | NIPPON ZEON CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-7084222-B2 | Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst | ZEON CORPORATION (JP) | 2006-08-01 | — | — | US | disclosed |
| US-6908970-B2 | Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization | ZEON CORPORATION (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20050014916-A1 | Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst | ZEON CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20030050406-A1 | Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization | ZEON CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-6486264-B1 | Process for producing hydrogenated ring-opening polymerization polymer of cycloolefin | ZEON CORPORATION (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1197509-A1 | PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | Nippon Zeon Co., Ltd. (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014916-A1 | Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst | POR, CAD, HRH1 | MAPT 2369/4885ALDH1A1 3138/4885GLA 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.